ArticleArthritis research & therapy2026
Increased soluble CD200 in serum of SLE patients does not reflect disease activity or affect CD200R1 function in T cells.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lymphocyte activation gene 3 in autoimmune disease: from molecular mechanisms to clinical applications.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCD200 receptor 1 (CD200R) is an inhibitory immune receptor that is functionally altered in people with the interferonopathy systemic lupus erythematosus (SLE): soluble CD200 is increased in serum, and on monocytes CD200R stimulates inflammation in SLE patients. However, CD200R is not studied on T cells in SLE. Here we assessed CD200R expression on immune cells, function on T cells, and whether sCD200 in serum correlates with diseases activity in SLE.
methodsIn a cross-sectional cohort study with SLE, antiphospholipid syndrome, primary Sjögren’s syndrome, and systemic sclerosis we measured CD200R and CD200 membrane expression using flowcytometry, and determined soluble CD200R (sCD200R) and CD200 (sCD200) concentrations in serum. In a prospective cohort study in 100 patients with SLE with a two-year follow-up, we collected consecutive serum and urine samples, and correlated soluble CD200R and CD200 to disease activity.
resultsCD200R expression was increased on T cells from SLE patients compared to controls, but not in other interferonopathies. Ligation of CD200R in vitro inhibited cytokine production by T cells from controls as well as from SLE patients. In SLE patients, concentrations of sCD200 were increased in circulation, while sCD200R concentrations were decreased. sCD200 was increased in patients with clinically active SLE, although there was no correlation with disease flares within patients.
conclusionOur findings indicate that CD200R is a functional inhibitory receptor on T cells in SLE. In addition, we found that soluble CD200 in serum is increased in SLE but does not change during SLE flares. Together, considering the potential therapeutical benefit of agonizing inhibitory receptors in autoimmune disease, this makes CD200R an interesting target for treating SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.